Form 4: Vera Therapeutics Director, Patrick G. Enright, Reports Stock Option Grant
SEC Form 4 Filing
Director Patrick G. Enright reports acquisition of 14,000 stock options in Vera Therapeutics, Inc.
Summary
- On May 14, 2025, Patrick G. Enright, a director of Vera Therapeutics, Inc., acquired 14,000 stock options.
- The exercise price of these options is $21.19.
- The options vest fully on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, contingent upon continuous service.
- The options also vest fully upon a change in control, subject to continuous service through the date of such change in control.
- The expiration date for these options is May 13, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative on its own.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.
Comparison to Industry Standards
- Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry.
- The vesting schedule and exercise price are typical for such grants, aligning the interests of the director with those of the shareholders.
- Comparable companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their compensation packages for directors and executives.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 05/14/2025 | Date of transaction: Patrick G. Enright acquired 14,000 stock options. |
| 05/16/2025 | Date of Form 4 filing. |
| 2026 | Options vest on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting. |
| 05/13/2035 | Expiration date of the stock options. |
Keywords
stock options, Form 4, director, VERA, Vera Therapeutics, beneficial ownership, Enright, Patrick G. Enright
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.